Herbs (Global Traditional) · Amazonian
Pau d'Arco (Tabebuia impetiginosa) (Tabebuia impetiginosa)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Pau d'arco (Tabebuia impetiginosa) is an Amazonian tree bark containing lapachol and beta-lapachone as primary bioactive compounds. These naphthoquinones demonstrate anti-inflammatory and potential anti-cancer effects by inhibiting NF-κB signaling and inducing oxidative stress in abnormal cells.
Pau d'Arco derives from the inner bark of Tabebuia impetiginosa (also known as Handroanthus impetiginosus), a tree native to the rainforests of South America, particularly Brazil where it is called 'ipê roxo.' The material is typically harvested from the heartwood and inner bark, with extracts prepared via decoction, infusion, or solvent extraction using water, methanol, ethyl acetate, chloroform, or hexane.
No key human RCTs, clinical trials, or meta-analyses directly testing T. impetiginosa extracts were found; evidence is limited to preclinical in vitro and animal studies. One small clinical study tested related species T. avellanedae at 1050 mg/day for 8 weeks in healthy women with dysmenorrhea, finding it generally safe but not reporting efficacy outcomes. Isolated compounds like β-lapachone entered phase 2 trials for cancer, and BBI608/Napabucacin reached clinical development.
No clinically studied dosages are reported for T. impetiginosa in human trials. Preclinical animal studies used 100-400 mg/kg ethanol extract for anti-inflammatory effects. One related species (T. avellanedae) was tested at 1050 mg/day unstandardized powder for 8 weeks. Consult a healthcare provider before starting any new supplement.
Pau d'Arco bark is not consumed as a conventional food source and thus lacks a traditional macronutrient/micronutrient profile. Its nutritional and bioactive composition is characterized primarily by secondary metabolites rather than macronutrients. Key bioactive compounds include: Naphthoquinones — lapachol (primary active constituent, typically 2–7% dry weight of inner bark) and beta-lapachone (present in smaller quantities, estimated 0.1–0.5% dry weight); Anthraquinones — tabebuin and related derivatives; Furanonaphthoquinones — including 5-hydroxy-2-(1-methylethyl) furanonaphthoquinone; Iridoids and flavonoids — quercetin glycosides and other polyphenols present at trace concentrations (~0.5–2% total polyphenols in ethanolic extracts); Benzoic acid derivatives and cyclopentene diones. Mineral content in dried bark includes modest levels of calcium (~200–400 mg/100g dry weight), potassium (~300–500 mg/100g), iron (~5–15 mg/100g), and magnesium (~80–150 mg/100g), though these values are approximate and sourced from limited analyses. Protein content is negligible (<2% dry weight), dietary fiber is present (~20–35% dry weight as structural bark material but not bioavailable in tea preparations). Lapachol bioavailability from aqueous tea infusions is notably low due to poor water solubility; ethanolic/lipid-based preparations significantly enhance absorption. Beta-lapachone exhibits greater aqueous solubility than lapachol. Total naphthoquinone content in standardized commercial extracts is typically reported at 3–5% lapachol equivalent.
Pau d'arco's naphthoquinone compounds, particularly lapachol and beta-lapachone, inhibit nuclear factor-κB (NF-κB) signaling pathways, reducing production of inflammatory cytokines including TNF-α, IL-1β, and IL-6. These compounds also generate reactive oxygen species in cancer cells while sparing healthy cells, potentially triggering apoptosis through mitochondrial dysfunction.
In vitro studies using human peripheral blood mononuclear cells showed pau d'arco bark extracts at 32-100 µg/mL concentrations significantly reduced inflammatory cytokine production, in some cases outperforming cyclosporine A. Laboratory studies demonstrate anti-cancer activity against various cell lines, but human clinical trials are lacking. Current evidence is limited to preliminary in vitro research with no published human intervention studies to confirm therapeutic efficacy or optimal dosing.
Pau d'arco may cause nausea, dizziness, and diarrhea at higher doses, with lapachol potentially causing anticoagulant effects. It may interact with blood-thinning medications like warfarin and could enhance effects of immunosuppressive drugs. Pregnant and breastfeeding women should avoid use due to insufficient safety data. Individuals with bleeding disorders or scheduled for surgery should discontinue use at least two weeks prior.
